Clinical trial · Interventional
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis (FAP) Patients
NCT00248053CI-TRIAL-00008051withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Subsequent data generated by our collaborators have shown efficacy with curcumin and quercetin in 5 patients in a non placebo controlled trial.
Summary
Brief summary (as posted)
The purpose of this study is to assess if curcumin, a commonly used food spice, can regress colorectal adenomatous polyps in patients with familial adenomatous polyposis, an inherited form of colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Familial Adenomatous Polyposis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| curcumin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Lower GI
- interventionNames
- Drug: curcumin
Primary outcomes (1)
- measure
- polyp number and size
- timeFrame
- one year
Secondary outcomes (1)
- measure
- side effects and medication compliance
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Familial adenomatous polyposis * 18 years of age or older * 5 or more adenomas of colorectum or ileum Exclusion Criteria: * Female patient of child bearing age not on effective birth control pills * Pregnant women * White blood cell (WBC) count less than 4000 * Platelets (Plts) less than 100,000 * Blood urea nitrogen (BUN) greater than 25 * Creatine greater than 1.5 * Patients unable to stop non-steroidal anti-inflammatory drugs (NSAIDs) during duration of trial * Malignancy * Patient with active bacterial infections of gastroesophageal reflux disease or peptic ulcer disease * Patient on warfarin or anti-platelet drugs
References
Publications (0)
Data not yet available
No reference posted for this study.